Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial
在RAS/BRAF野生型且初始不可切除的结直肠癌肝转移患者中，西妥昔单抗联合FOLFOXIRI方案与西妥昔单抗联合FOLFOX方案作为转换治疗方案的比较（TRICE试验）：一项随机对照试验
期刊:PLoS Medicine
影响因子:9.9
doi:10.1371/journal.pmed.1004389
Wang, De-Shen; Ren, Chao; Li, Shan-Shan; Fong, William Pat; Wu, Xiao-Jun; Xiao, Jian; Li, Bin-Kui; Zheng, Yun; Ding, Pei-Rong; Chen, Gong; Qiu, Miao-Zhen; Wang, Zhi-Qiang; Wang, Feng-Hua; Luo, Hui-Yan; Wang, Feng; Wang, Xiao-Zhong; Wang, Ling-Yun; Xie, De-Jin; Chen, Tao; Li, Li-Ren; Lu, Zhen-Hai; Zhai, Xiao-Hui; Liu, Tian-Shu; Yuan, Ying; Chen, Jia-Qi; Tan, Qiong; Pan, Zhi-Zhong; Wan, De-Sen; Zhang, Rong; Yuan, Yun-Fei; Xu, Rui-Hua; Li, Yu-Hong
